» Articles » PMID: 33403035

Upregulation of MiR-1254 Promotes Hepatocellular Carcinoma Cell Proliferation, Migration, and Invasion Via Inactivation of the Hippo-YAP Signaling Pathway by Decreasing PAX5

Overview
Journal J Cancer
Specialty Oncology
Date 2021 Jan 6
PMID 33403035
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidence suggests that microRNAs (miRNAs) affect the progression of hepatocellular carcinoma (HCC). However, the exact function and mechanism of miR-1254 in HCC remains unclear. This study explored the effects of miR-1254 on the biological behavior of HCC cells and determined the underlying mechanism. RT-qPCR was used to detect the expression of miR-1254. Gain- or loss-of-function assays determined if miR-1254 affected the biological function of HCC cells . Dual luciferase reporter assays confirmed the target gene of miR-1254. Tumor xenografts in mice were used to explore the effects of miR-1254 on tumorigenesis and metastasis of HCC. miR-1254 was upregulated in HCC tissues and cell lines and linked to larger tumor size, aggressive vascular invasion and higher Edmondson grade. Lentiviral-based overexpression and knockdown experiments indicated that miR-1254 promoted proliferation, migration, invasion, and the epithelial-mesenchymal transition of HCC cells. The paired box gene 5 (PAX5) was downregulated in HCC tissues, negatively correlated with miR-1254 expression, and confirmed to be a direct target of miR-1254. Restoration of PAX5 reversed the effects of miR-1254 on the biological behavior of HCC cells. Advanced mechanism studies suggested that PAX5 might mediate miR-1254 by regulating the Hippo signaling pathway. Tumor xenografts in mice confirmed that miR-1254 promoted tumorigenesis and metastasis, and led to poor survival. In conclusion, miR-1254 promoted proliferation, migration, and invasion of HCC cells via decreasing Hippo signaling through targeting PAX5 and . This miRNA might be a therapeutic target for HCC.

Citing Articles

Novel insights into the impact of liver inflammatory responses on primary liver cancer development.

Ait-Ahmed Y, Lafdil F Liver Res. 2025; 7(1):26-34.

PMID: 39959704 PMC: 11791919. DOI: 10.1016/j.livres.2023.01.001.


Paired Box 5 (PAX5) Gene Has Diagnostic and Prognostic Potential in Nasopharyngeal Carcinoma.

Ye J, Huang X, Qin W, Liang P, Zhao J, Ye Y Int J Gen Med. 2024; 17:487-501.

PMID: 38348125 PMC: 10860600. DOI: 10.2147/IJGM.S442835.


Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.

Shi H, Zou Y, Zhong W, Li Z, Wang X, Yin Y J Cancer Res Clin Oncol. 2023; 149(16):15311-15322.

PMID: 37608027 DOI: 10.1007/s00432-023-05272-2.


Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy.

Chen W, Chang T, Chou H, Cheng M, Hong J, Hsieh Y Int J Mol Sci. 2023; 24(11).

PMID: 37298699 PMC: 10253890. DOI: 10.3390/ijms24119748.


Plasma miR-1254 as a predictive biomarker of chemosensitivity and a target of nucleic acid therapy in esophageal cancer.

Takashima Y, Komatsu S, Ohashi T, Kiuchi J, Nishibeppu K, Kamiya H Cancer Sci. 2023; 114(7):3027-3040.

PMID: 37190912 PMC: 10323105. DOI: 10.1111/cas.15830.


References
1.
Orom U, Nielsen F, Lund A . MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4):460-71. DOI: 10.1016/j.molcel.2008.05.001. View

2.
Guan L, Li T, Ai N, Wang W, He B, Bai Y . MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1):417. PMC: 6796342. DOI: 10.1186/s13046-019-1417-3. View

3.
Harquail J, Leblanc N, Landry C, Crapoulet N, Robichaud G . Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors. J Mammary Gland Biol Neoplasia. 2018; 23(3):177-187. DOI: 10.1007/s10911-018-9404-4. View

4.
Schafer B . Emerging roles for PAX transcription factors in cancer biology. Gen Physiol Biophys. 1998; 17(3):211-24. View

5.
Li B, Chen P, Wang J, Wang L, Ren M, Zhang R . MicroRNA-1254 exerts oncogenic effects by directly targeting RASSF9 in human breast cancer. Int J Oncol. 2018; 53(5):2145-2156. DOI: 10.3892/ijo.2018.4530. View